Pulmonary Delivery of Drugs and Biologics
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 9596
Interests: drug discovery; drug repurposing; pulmonary drug delivery; lung cancer; pulmonary hypertension; respiratory pathophysiology
Interests: inhaled drug delivery; thermostable vaccines; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Drug delivery via the pulmonary route enables the direct administration of drugs and biologics into the lung for the treatment of both local and systemic diseases. Lungs, as a delivery site, offer several advantages, such as a large surface area, dense vasculature, lower enzymatic activity than the gut, and a thin alveolar epithelium that allows for rapid absorption and the immediate onset of action. All of these benefits make it an excellent choice for a non-invasive route of administration. Furthermore, the presence of a high density of immune cells, particularly antigen-presenting cells such as alveolar macrophages and dendritic cells, make it ideal for vaccine delivery, and aid in the generation of a strong mucosal and systemic immunity.
For successful delivery into the lungs, the right combination of the formulation and the device is needed to generate particles or droplets of an appropriate size in order to achieve deposition in the respirable region of the airways. Recent advances in the field of formulation design and pharmaceutical engineering show significant progress in achieving efficient deep lung deposition.
In this review, we would like to focus on the latest advancements in the areas of nanoparticle-based pulmonary delivery, nebulizer- and dry powder-based formulations, pulmonary vaccine delivery, formulations containing drugs and biologics for lung delivery, and targeted delivery to specific regions of the lungs.
Dr. Vivek Gupta
Dr. Nitesh K. Kunda
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pulmonary drug delivery
- metered-dose inhaler
- dry powder inhaler
- vaccine delivery
- mucosal delivery